參考文獻 |
[1] P. Cohen, “The role of protein phosphorylation in neural and hormonal control of cellular
activity,” Nature, vol. 296, no. 5858, pp. 613–620, 1982.
[2] G.Manning,D.B.Whyte,R.Martinez,T.Hunter,andS.Sudarsanam,“Theproteinkinase
complement of the human genome,” Science, vol. 298, no. 5600, pp. 1912–1934, 2002.
[3] D. D. Wiredja, M. Koyutürk, and M. R. Chance, “The ksea app: A web-based tool for
kinase activity inference from quantitative phosphoproteomics,” Bioinformatics, vol. 33,
no. 21, pp. 3489–3491, 2017.
[4] R. Beekhof et al., “Inka, an integrative data analysis pipeline for phosphoproteomic in
ference of active kinases,” Molecular Systems Biology, vol. 15, no. 4, e8250, 2019.
[5] P. Casado and P. R. Cutillas, “A self-validating quantitative mass spectrometry method
for assessing the accuracy of high-content phosphoproteomic experiments,” Molecular &
Cellular Proteomics, vol. 10, no. 1, 2011.
[6] H.-D.Huang, T.-Y. Lee, S.-W. Tzeng, and J.-T. Horng, “Kinasephos: A web tool for iden
tifying protein kinase-specific phosphorylation sites,” Nucleic Acids Research, vol. 33,
no. suppl_2, W226–W229, 2005.
[7] S.Yılmaz, M. Ayati, D. Schlatzer, A. E. Çiçek, M. R. Chance, and M. Koyutürk, “Robust
inference of kinase activity using functional networks,” Nature Communications, vol. 12,
no. 1, p. 1177, 2021.
[8] P. Casado et al., “Kinase-substrate enrichment analysis provides insights into the het
erogeneity of signaling pathway activation in leukemia cells,” Science Signaling, vol. 6,
no. 268, rs6–rs6, 2013.
[9] S.R.Piersma,A.Valles-Marti, F. Rolfs, T. V. Pham, A.A.Henneman,andC.R.Jiménez,
“Inferring kinase activity from phosphoproteomic data: Tool comparison and recent ap
plications,” Mass Spectrometry Reviews, e21808, 2022.
[10] E. H. Wilkes, P. Casado, V. Rajeeve, and P. R. Cutillas, “Kinase activity ranking using
phosphoproteomics data (karp) quantifies the contribution of protein kinases to the regu
lation of cell viability,” Molecular & Cellular Proteomics, vol. 16, no. 9, pp. 1694–1704,
2017.
[11] M.V.Kuleshovetal., “Kea3: Improved kinase enrichment analysis via data integration,”
Nucleic Acids Research, vol. 49, no. W1, W304–W316, 2021.
[12] S. Crowl, B. T. Jordan, H. Ahmed, C. X. Ma, and K. M. Naegle, “Kstar: An algorithm to
predict patient-specific kinase activities from phosphoproteomic data,” Nature Commu
nications, vol. 13, no. 1, p. 4283, 2022.
[13] S.Vasaikaretal.,“Proteogenomicanalysisofhumancoloncancerrevealsnewtherapeutic
opportunities,” Cell, vol. 177, no. 4, pp. 1035–1049, 2019.
[14] T. Zhang et al., “Interrogating kinase–substrate relationships with proximity labeling and
phosphorylation enrichment,” Journal of Proteome Research, vol. 21, no. 2, pp. 494–506,
2022.
[15] M. Hijazi, R. Smith, V. Rajeeve, C. Bessant, and P. R. Cutillas, “Reconstructing kinase
network topologies from phosphoproteomics data reveals cancer-associated rewiring,”
Nature Biotechnology, vol. 38, no. 4, pp. 493–502, 2020.
[16] J. Adachi et al., “Systematic identification of alk substrates by integrated phosphopro
teome and interactome analysis,” Life Science Alliance, vol. 5, no. 8, 2022.
[17] N. Sugiyama, H. Imamura, and Y. Ishihama, “Large-scale discovery of substrates of the
human kinome,” Scientific Reports, vol. 9, no. 1, p. 10503, 2019.
[18] R. Ma, S. Li, W. Li, L. Yao, H.-D. Huang, and T.-Y. Lee, “Kinasephos 3.0: Redesign and
expansion of the prediction on kinase-specific phosphorylation sites,” Genomics, Pro
teomics and Bioinformatics, vol. 21, no. 1, pp. 228–241, 2023.
[19] R. Linding et al., “Networkin: A resource for exploring cellular phosphorylation net
works,” Nucleic Acids Research, vol. 36, no. suppl_1, pp. D695–D699, 2007.
[20] P. V. Hornbeck et al., “Phosphositeplus: A comprehensive resource for investigating the
structure and function of experimentally determined post-translational modifications in
man and mouse,” Nucleic Acids Research, vol. 40, no. D1, pp. D261–D270, 2012.
[21] P. Lo Surdo et al., “Signor 3.0, the signaling network open resource 3.0: 2022 update,”
Nucleic Acids Research, vol. 51, no. D1, pp. D631–D637, 2023.
[22] K.O’sheaandR.Nash,“Anintroductiontoconvolutionalneuralnetworks,”arXivpreprint
arXiv:1511.08458, 2015.
[23] V. Sze, Y.-H. Chen, T.-J. Yang, and J. S. Emer, “Efficient processing of deep neural net
works: A tutorial and survey,” Proceedings of the IEEE, vol. 105, no. 12, pp. 2295–2329,
2017.
[24] B. Nuche-Berenguer, I. Ramos-Álvarez, and R. Jensen, “The p21-activated kinase, pak2,
is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events,” Biochimica et Biophysica Acta (BBA)-Molecular
Basis of Disease, vol. 1862, no. 6, pp. 1122–1136, 2016.
[25] M. Alfaidi, U. Bhattarai, and A. W. Orr, “Nck1, but not nck2, mediates disturbed flow
induced p21-activated kinase activation and endothelial permeability,” Journal of the
American Heart Association, vol. 9, no. 11, e016099, 2020.
[26] KEGG PATHWAY: Adrenergic signaling in cardiomyocytes- Homo sapiens (human) —
genome.jp, https://www.genome.jp/pathway/hsa04261, [Accessed 05-06-2024].
[27] Harmonizome — maayanlab.cloud, https://maayanlab.cloud/Harmonizome/, [Ac
cessed 05-06-2024].
[28] L.-I.Hsuetal.,“Pathwayanalysisofgenome-wideassociationstudyinchildhoodleukemia
amonghispanics,”CancerEpidemiology,Biomarkers&Prevention,vol.25,no.5,pp.815
822, 2016.
[29] X. Ni et al., “Long non-coding rna zeb1-as1 promotes colon adenocarcinoma malignant
progression via mir-455-3p/pak2 axis,” Cell Proliferation, vol. 53, no. 1, e12723, 2020.
[30] J. Luo et al., “Establishment of an immune-related gene pair model to predict colon ade
nocarcinoma prognosis,” BMC cancer, vol. 20, pp. 1–11, 2020.
[31] C.Hofmann,M.Shepelev,andJ.Chernoff,“Thegeneticsofpak,”Journalofcell science,
vol. 117, no. 19, pp. 4343–4354, 2004.
[32] E. Sementino et al., “Inactivation of p21-activated kinase 2 (pak2) inhibits the develop
ment of nf2-deficient tumors by restricting downstream hedgehog and wnt signaling,”
Molecular Cancer Research, vol. 20, no. 5, pp. 699–711, 2022.
[33] R. Santoro, C. Carbone, G. Piro, P. J. Chiao, and D. Melisi, “Tak-ing aim at chemore
sistance: The emerging role of map3k7 as a target for cancer therapy,” Drug Resistance
Updates, vol. 33, pp. 36–42, 2017.
[34] S. Ikram, A. Rege, M. Y. Negesse, A. G. Casanova, N. Reynoird, and E. M. Green, “The
smyd3-map3k2 signaling axis promotes tumor aggressiveness and metastasis in prostate
cancer,” Science Advances, vol. 9, no. 46, eadi5921, 2023.
[35] K. Nguyen et al., “Nek family review and correlations with patient survival outcomes in
various cancer types,” Cancers, vol. 15, no. 7, p. 2067, 2023. |